Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
Armando Santoro(IRCCS Humanitas Research Hospital), Alexia Bertuzzi(Humanitas University), Alessandro Comandone(Ospedale Humanitas Gradenigo), Antonella Boglione(Ospedale Humanitas Gradenigo), Héctor Soto Parrà, Romano Fabio Lutman(Humanitas University), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Umberto Basso(Istituto Oncologico Veneto), Rita De Sanctis(Humanitas University), Ilaria Marcon(Ospedale di Circolo e Fondazione Macchi), Elisa Maria Stroppa(Guglielmo da Saliceto Hospital)
Cited by 54
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579